• About BAYCELLator
  • Projects
      Project 1
        Project 2
          Project 3
            Project 4
              Project 5
                Project 6
                  Project 7
                    Project 8
                  • Publications
                  1. The Bavarian Cell Therapy Catalyst
                  2. Projects
                  3. Project 1

                  Project 1

                  Development of a chimeric antigen receptor that specifically and selectively recognizes acute myeloid leukemia (AML) blasts

                  Academic Partners
                  Prof. Dr. med. Sebastian Kobold
                  Abt. Klinische Pharmakologie, Klinikum der Universität München
                  publications
                  more on the person
                  Emre Erdogan
                  Doctoral student. AG Kobold
                  Industry Partners
                  Dr. rer. nat. Christian Thirion
                  Revvity Gene Delivery (formerly SIRION Biotech)
                  Dr. rer. nat. Bianca Volkmann
                  Revvity Gene Delivery (formerly SIRION Biotech)
                  SIRION Biotech GmbH
                  Revvity
                  Collaborators

                  Prof. Dr. med. Marion Subklewe

                  Medizinische Klinik III, KUM

                  Prof. Dr. med. Michael von Bergwelt 

                  Medizinische Klinik III, KUM

                  Prof. Dr. med. Louisa von Baumgarten 

                  Neurochirurgische Klinik, KUM

                  PD Dr. rer. nat. Thomas Nerreter 

                  Medizinische Klinik II, UKW

                  Prof. Dr. med. Tobias Feuchtinger 

                  Universitätsklinikum Freiburg

                  Prof. Dr. med. Michael Hudecek 

                  Medizinische Klinik II, UKW

                  Prof. Dr. med. Hermann Einsele 

                  Medizinische Klinik II, UKW

                  Project Summary

                  Acute myeloid leukemia (AML) is the most common acute leukemia in adults and has been diagnosed worldwide in 150,000 people in 2020 only. Despite an initial curative approach, many patients do not respond or relapse after initial response. As a result, 100,000 people died from AML in the same period [1]. In the relapsed situation, allogenic stem cell transplantation is the only curative treatment, yet this applies to at most 25% of those treated, demonstrating the great medical need for innovative therapies [2]. So far, the development of new immunotherapies, such as chimeric antigen receptor (CAR)-modified T cells, has not been as successful as anticipated. This is due to their level of efficacy or their association with severe toxicity effects.

                  CAR (chimeric antigen receptors) are synthetic receptors consisting of the fusion of the variable part of an antibody with T cell activating and costimulatory domains [3]. These receptors can be introduced into immune cells, especially T cells, by gene transfer. This allows the target cell the ability to recognize and lyse antigen-positive cells [4]. This procedure has been successfully applied and approved for clinical use against CD19 as an antigen associated with lymphoma and B-cell leukaemia [5]. Our aim is to adapt this technology against AML blasts.

                  So far, attempts using CAR T cells directed against prominent targets (CD33 o CD123) in AML blasts have not been entirely successful. This is mainly because the presence of the targets on haematopoietic stem cells leads to the depletion of human haematopoiesis [6, 7].

                  The current literature suggests that leukemia is caused by mutations in different hematopoietic progenitor cells [8]. This implies that AML blasts and their stem cells share many phenotypic similarities with the cells healthy hematopoiesis. Consequently, this leads to a lack of discrimination of AML-targeted therapies and thus, among others, to severe haematological toxicities [9]. Therefore, the urge of finding better targets for AML. Such structures would have the potential to allow immunotherapies in AML and would have a great medical and economic potential.

                  In preliminary work, we could identify, for the first time antigens with predicted superior selectivity for AML blasts [10]. We developed CAR against these targets and demonstrated superior efficacy and discriminatory capacity in preclinical models. To now advance to clinical development, the parties will establish technologies and a manufacturing process involving GMP materials and media developed by Sirion/Revvity that comply with regulatory requirements, while preserving the previously described properties.  

                  Project related publications

                  1. Sung, H., et al., Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 2021. 71(3): p. 209-249.

                  2. Shimoni, A., et al., Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the Acute Leukemia Working Party of EBMT. Blood Cancer J, 2019. 9(12): p. 88.

                  3. Tokarew, N., et al., Teaching an old dog new tricks: next-generation CAR T cells. Br J Cancer, 2019. 120(1): p. 26-37.

                  4. Benmebarek, M.R., et al., Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells. Int J Mol Sci, 2019. 20(6).

                  5. Lesch, S., et al., Determinants of response and resistance to CAR T cell therapy. Semin Cancer Biol, 2020. 65: p. 80-90.

                  6. Wang, Q.S., et al., Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia. Mol Ther, 2015. 23(1): p. 184-91.

                  7. Yao, S., et al., Donor-Derived CD123-Targeted CAR T Cell Serves as a RIC Regimen for Haploidentical Transplantation in a Patient With FUS-ERG+ AML. Front Oncol, 2019. 9: p. 1358.

                  8. Khaldoyanidi, S., et al., Immune Biology of Acute Myeloid Leukemia: Implications for Immunotherapy. J Clin Oncol, 2021. 39(5): p. 419-432.

                  9. Mardiana, S. and S. Gill, CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future Directions. Front Oncol, 2020. 10: p. 697.

                  10. Gottschlich, A., et al., Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia. Nat Biotechnol, 2023.

                  Contact Details

                  Klinikum der Universität München. Abteilung Klinische Pharmakologie 

                  Lindwurmstrasse 2a
                  80337 München
                  +49 089 4400 57322 Klinische Pharmakologie, KUM

                  Supported by the Bavarian Research Foundation - Bayerische Forschungsstiftung

                  Contact Form

                  I agree to the data usage notice (see below). *

                  Security question (I'm not a robot!)

                  Data Usage Notice

                  Your personal data will be treated confidentially by us and will only be used to contact you by e-mail, telephone and/or in writing as part of this contact. Your information will be adequately protected against access by third parties and collected, processed and used in accordance with the provisions of the Federal Data Protection Act. The provision of your personal data, in particular your data on your health, is voluntary. If necessary, your request will be forwarded to the responsible departments or persons within the Munich University Hospital (KUM). In this context, there is the possibility that non-medical staff of the clinic may gain knowledge of the information you have disclosed. This information will not be passed on or transmitted to third parties outside the clinic. Your data will be deleted no later than 3 months after your information has been evaluated or forwarded to the responsible office. You can revoke your consent to the earmarked processing and use of the data at any time in writing without giving reasons. Your stored data will then be deleted immediately within the framework of legal regulations. The relevant information about your request will be sent or forwarded to you in unencrypted form at the email address you provided, without providing any information about your health. This poses a risk under data protection law. We will only send requested patient and personal application documents to a reasonable extent by post if you have given your postal address. Please also note our general data protection declaration

                  Login for editors
                  Imprint | Data-Safety

                  The Bavarian...

                  • About BAYCELLator
                  • Projects
                    • Project 1
                    • Project 2
                    • Project 3
                    • Project 4
                    • Project 5
                    • Project 6
                    • Project 7
                    • Project 8
                  • Publications